Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 · 2 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| COVID-19 Vaccine | BIOLOGICAL | Receive SOC mRNA SARS-CoV-2 vaccine IM |
| Diagnostic Laboratory Biomarker Analysis | OTHER | Correlative studies |
| Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 | BIOLOGICAL | Given IM |
| Placebo Administration | DRUG | Given IM in the non-dominant upper arm |
| Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 | BIOLOGICAL | Given IM in the non-dominant upper arm |
It is an investigational vaccine candidate designed to prevent COVID-19 infection. It is being developed by GeoVax Labs, Inc. under the ticker GOVX. The vaccine is based on a synthetic modified vaccinia Ankara (MVA) platform and is in Phase 2 clinical development. It has been studied in one completed clinical trial.
It is being developed for the prevention of COVID-19 infection. The vaccine candidate is intended to protect against SARS-CoV-2, the virus that causes COVID-19. It is currently in Phase 2 clinical development and has been evaluated in a completed Phase 1/2 trial.
GeoVax Labs, Inc., which trades under the ticker GOVX, is developing the Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1. The company is responsible for the clinical development of this COVID-19 vaccine candidate.
The Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 is in Phase 2 clinical development. It has completed one Phase 1/2 clinical trial. It is an investigational vaccine and has not been approved by the FDA.
The Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 has been studied in one completed clinical trial, NCT04639466, titled "A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection." This Phase 1/2 trial enrolled 119 participants and evaluated the vaccine for the prevention of COVID-19 infection.